Young Wendy B. purchased $100K of RAPP
Young Wendy B. purchased 3,789 shares of Rapport Therapeutics, Inc. (RAPP) at $26.39 on 2026-10-22.
How this was made
The 30-second read
Why it matters
The director's purchase adds a modest positive data point for Rapport Therapeutics, but the overall market impact is limited due to the small transaction size.
Market read
Primary insider purchase filing; modest relevance for traders tracking insider activity in small-cap biotech stocks.
What to watch
No accompanying corporate news or catalyst; the impact may be muted without broader context.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.
Ticker impact
Director Wendy B. Young purchased 3,789 shares of Rapport Therapeutics at $26.39, increasing her stake to 13,289 shares.
potential modest upside as market perceives the director's buy as a positive signal
The transaction size (~$100k) is modest for a micro‑cap biotech, but the insider is a director, which can attract attention from traders monitoring insider activity.
Market effects
Limited; may slightly boost sentiment in the biotech sector if investors view insider buying as a positive sign.
None
Minimal
Counterpoint
The purchase is too small to indicate material confidence; could be routine portfolio rebalancing.
Key entities
- CompanyRapport Therapeutics, Inc.
Biotech company focused on therapeutic development.
- IndividualWendy B. Young
Director of Rapport Therapeutics who made the purchase.
